From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Société Anonyme
Traded asEuronextBIM
Founded1963; 57 years ago (1963)
FounderDr Alain Mérieux
HeadquartersMarcy-l'Étoile, France
Area served
Key people
Alexandre Mérieux
(CEO) Dr Marcel Mérieux, Dr Charles Mérieux
Productsin vitro diagnostics
Revenue€2.4 billion (2018)
Number of employees
11 200 (2018)

bioMérieux (EuronextBIM) is a French multinational biotechnology company founded and headquartered in Marcy-l'Étoile, France. bioMérieux is present in 44 countries and serves more than 160 countries through a large network of distributors.[1]

bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases, cancer screening, and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.[2] bioMérieux is listed on the NYSE Euronext Paris stock exchange (BIM – ISIN: FR0010096479).[3]


bioMérieux had revenues of €2.7 billion as of 2019 with 90% of sales occurring outside France.[4] [1]


In 1897, Marcel Mérieux, former assistant to Louis Pasteur, founded the Mérieux Biological Institute, which later became Institut Mérieux. In 1963 Alain Mérieux founded BD Mérieux, of which he assumed total control in 1973. BD Mérieux would later become bioMérieux. The company expanded its services and offerings through product development, acquisitions and partnerships:

  • Api Systems, acquired in 1986[5]
  • Vitek Systems, acquired in 1988[6]
  • Organon Teknika, acquired in 2001 from Akzo Nobel[7]
  • Bacterial Barcodes, acquired in 2006[8]
  • Biomedics (Spain) and BTF (Australia), acquired in 2007[9]
  • AB Biodisk (Sweden), AviaraDx (bioTheragnostics today) (USA) and PML Microbiologicals (USA), acquired in 2008[10]
  • Meikang Biotech and of Shanghai Zenka Biotechnology, acquired in 2010[11]
  • AES Laboratoire and Argene (France), acquired in 2011[12]
  • RAS (India), a specialist in molecular biology, acquired in 2012
  • Partnership with Quanterix in 2012 for the development of a new generation of ultrasensitive, multiplex immunoassays.[13]
  • BioFire Diagnostics Inc., a privately held US-based company specialized in molecular biology,[14][15] acquired in 2014
  • BioMerieux molecular biology affiliate BioFire, LLC. opened the Alain Mérieux Center for Molecular Diagnostics in Salt Lake City, Utah[16] in 2017
  • Invisible Sentinel, A Philadelphia life sciences company that develops novel technology to quickly detect pathogens in food and beverages including wine and beer. [17]

Institut Mérieux, which belongs to the Mérieux family, is the main shareholder of bioMérieux. Jean-Luc Belingard is President, and Alexandre Mérieux is General Director.[18] *bioMérieux is listed on the stock exchange in 2004.[19]


List in 2019.[20]

Merieux Alliance 58,9%
Famille Dassault 5,10%
Jupiter Asset Management 4,62%
Sofina 2,12%
Oddo Bhf Asset Management 1,68%
Capital Research & Management 1,33%
Norges Bank Investment Management 1,29%
The Vanguard Group 0,95%
BlackRock Fund Advisors 0,62%
Candriam Belgium 0,61%


  1. ^
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^
  8. ^ "Archived copy". Archived from the original on 2017-11-07. Retrieved 2017-11-01.CS1 maint: archived copy as title (link)
  9. ^
  10. ^
  11. ^
  12. ^
  13. ^
  14. ^
  15. ^
  16. ^
  17. ^
  18. ^
  19. ^ "Archived copy". Archived from the original on 2017-11-07. Retrieved 2017-11-01.CS1 maint: archived copy as title (link)
  20. ^ Bourse, Zone. "Bourse : Cours de bourse en temps réel sur Actions, Indices, Forex, Matieres Premieres -". (in French). Retrieved 2019-04-18.

External links[edit]